The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
The DOI matches its Crossref record; 149 of the 149 references it cites were found in a registry or an index.
Abstract
After a pause of nearly 40 years in research into the effects of psychedelic drugs, recent advances in our understanding of the neurobiology of psychedelics, such as lysergic acid diethylamide (LSD), psilocybin and ketamine have led to renewed interest in the clinical potential of psychedelics in the treatment of various psychiatric disorders. Recent behavioural and neuroimaging data show that psychedelics modulate neural circuits that have been implicated in mood and affective disorders, and can reduce the clinical symptoms of these disorders. These findings raise the possibility that research into psychedelics might identify novel therapeutic mechanisms and approaches that are based on glutamate-driven neuroplasticity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It has been suggested that the persisting therapeutic effects of psychedelics are attributable to a similar biological mechanism (39, 40).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [39]
Citations
Cites
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 1×
“5 mg per kg), and this effect was sustained for at least 72 hour”
BackgroundA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · cited 1×
“Dissociative anaesthetics mimic the positive and the negative symptoms (social withdrawal and apathy) of schizophrenia through antagonism at NMDA ( N -methyl- D -aspartate) glutamate receptor”
BackgroundMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793 · cited 1×
“Systemic administration of non-competitive NMDA antagonists, such as ketamine, PCP and MK-801 (also known as dizocilpine), in rats markedly increases glutamate release in the mPF”
BackgroundDavis, H. S. (1966) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1966.03100200106038 · Cited by 1,719
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 1×
“and was rated as among the most personally meaningful experience”
Background(1990) · Springer eBooks · doi:10.1007/978-3-642-74034-3 · Cited by 1,523
Anis, N. A., Berry, S. C., Burton, N. R., & Lodge, D. (1983) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1983.tb11031.x · Cited by 1,399
(2009) · Elsevier eBooks · doi:10.1016/c2009-1-03742-3 · Cited by 1,308
Homayoun, H., & Moghaddam, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2213-07.2007 · Cited by 1,231 · cited 1×
“These effects are probably due to a blockade of NMDA receptors on GABA (γ-aminobutyric acid)-ergic interneuron”
Background
Research works printed but not linked: 6
- Hofmann, A. in Chemical Constitution and Pharmacodynamic Actions (ed. Burger, A.) 169–235 (M.Dekker, New York, 1968).
- Dittrich, A. in 50 Years of LSD. Current Status and Perspectives of Hallucinogens (eds Pletscher, A. & Ladewig, D.) 101–118 (Parthenon, New York, 1994).
- Hoffer, A. in The Uses and Implications of Hallucinogenic Drugs (eds Aaronson, B. & Osmond, H.) 357–366 (Hogarth Press, London, 1970).
- Leuner, H. in 50 Years of LSD: Current Status and Perspectives of Hallucinogen Research (eds Pletscher, A. & Ladewig, D.) 175–189 (Parthenon, New York, 1994).
- Crocket, R., Sandison, R. A. & Walk, A. in Proc. R. Med–Psychol. Assoc. (Lewis & Co., London, 1963).
- Leuner H. in Ethnopsychotherapie (eds Dittrich, A. & Scharfetter, C.) 151–161 (Enke, Stuttgard, 1987)
Cited by
Items 501–600 of 721
Werle, I., Guimarães, F. S., SANTOS, R. G. D., Hallak, J. E. C., & Bertoglio, L. J. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2025.11.009 · Cited by 5
Sanitizing psychedelics: the biopolitics of non-hallucinogenic psychoplastogens
Hartogsohn, I. (2026) · BioSocieties · doi:10.1057/s41292-025-00377-y · Cited by 5
Ip, C.-T., Olbrich, S., de Bardeci, M., Monn, A., Ort, A., Smallridge, J. W., & Vollenweider, F. X. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111626 · Cited by 5
Self-citationHow to set up a psychedelic study: Unique considerations for research involving human participants
Glennon, M. J., Bird, C., Yadav, P., Kleine, P., Suseelan, S., Boman-Markaki, C., Kotoula, V., Butler, M., Leech, R., Roseman, L., et al. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106657 · Cited by 5
Bender, D. A., & Siegel, J. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00043-9 · Cited by 4
The Acute and Chronic Effects of Ketamine as Revealed by Noninvasive Brain Imaging
Li, M., & Walter, M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800212-4.00064-9 · Cited by 3
Serotonin and the Brain: Exploring the 5-HT System's Role in Depression
McLaughlin, L. (2023) · Cornell Undergraduate Research Journal · doi:10.37513/curj.v2i1.715 · Cited by 6
Psychedelika in der Psychiatrie: Einführung und Stand klinischer Studien
Herwig, U. (2024) · Nervenheilkunde · doi:10.1055/a-2233-4301 · Cited by 3
Neurobiologie und Wirkmodelle zu Psychedelika
Herwig, U., Avram, M., Borgwardt, S., & Aicher, H. (2024) · Nervenheilkunde · doi:10.1055/a-2261-0745 · Cited by 3
Rudy, L. M., & Godlewski, M. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157233 · Cited by 5
“Studies involving the deactivation of 5-HT2A receptors have shown that they are essential for the promotion of hallucinogenesis, as blocking them prevents the characteristic perceptual effects of psychedelics such as LSD or psilocybin [55,56].”
Acute and Long-Term Effects of Ayahuasca on (Higher-Order) Cognitive Processes
Mason, N. L., & Kuypers, K. P. C. (2021) · Springer eBooks · doi:10.1007/978-3-030-55688-4_7 · Cited by 4
From Psychiatry to Flower Power and Back Again: The Amazing Story of Lysergic Acid Diethylamide
Mucke, H. A. (2016) · Assay and Drug Development Technologies · doi:10.1089/adt.2016.747 · Cited by 4
“26 In 2014, results from the first double-blind, randomized controlled human trial of LSD in more than 40 years were published.”
Sontheimer, H. W. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800244-5.00012-4 · Cited by 3
Hendricks, P. S., & Grob, C. S. (2016) · Springer eBooks · doi:10.1007/978-3-319-32672-6_14 · Cited by 3
Hallucinogen Use in College Students: Current Trends and Consequences of Use
Jia, L. S., & Gold, J. A. (2020) · Current Psychopharmacologye · doi:10.2174/2211556009666200311140404 · Cited by 4
Antipsychotic natural products
Skalicka‐Woźniak, K., & Gertsch, J. (2020) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2020.03.004 · Cited by 4
Sueur, C. (2018) · Psychotropes · doi:10.3917/psyt.233.0125 · Cited by 6
Hallucinogens and Related Compounds
Grob, C. S., & de Ríos, M. D. (2012) · Wiley eBooks · doi:10.1002/9781118340851.ch21 · Cited by 5
Roberts, A. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3944724 · Cited by 5
Kaldewaij, R., Salamone, P., Enmalm, A., Östman, L., Pietrzak, M., Karlsson, H., Löfberg, A., Gauffin, E., Samuelsson, M., Gustavson, S., et al. (2023) · doi:10.31234/osf.io/w3ftk · Cited by 3
Fernández‐Borkel, T., Borkel, L. F., Rojas‐Hernández, J., Hernández‐Álvarez, E., Hernández, D. J. Q., Ponti, L. G., & Henríquez‐Hernández, L. A. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00445 · Cited by 6
Serotonergic psychedelics for depression: A comprehensive overview
Wingert, A. M., Agnorelli, C., Peill, J., Reed, S., Nutt, D. J., & Erritzoe, D. (2025) · International Review of Neurobiology · doi:10.1016/bs.irn.2025.04.009 · Cited by 3
Psilocin fosters neuroplasticity in iPSC-derived human cortical neurons
Schmidt, M., Hoffrichter, A., Davoudi, M., Horschitz, S., Lau, T., Meinhardt, M. W., Spanagel, R., Ladewig, J., Köhr, G., & Koch, P. (2026) · eLife · doi:10.7554/elife.104006.3 · Cited by 10
Neuroplasticity and Neuro-Generation: The Promise of Psychedelics in Dementia Care
Soylemez, K. K., de Boo, E. M., Susuzlu, A., & Lusher, J. M. (2025) · Psychoactives · doi:10.3390/psychoactives4030031 · Cited by 2
“Controlled clinical trials have demonstrated promising outcomes, particularly for patients with treatment-resistant forms of depression and anxiety [43].”
How three different theories of depression converge at inflammation
Baumberger, B., Batey, L., & Hashemi, P. (2025) · Discover Mental Health · doi:10.1007/s44192-025-00312-4 · Cited by 2
“It is well known that psychedelics are neuroplastic agents [69], and after some clinical success using psychedelics to treat obsessive compulsive disorder [70] and tobacco [71] and alcohol addiction [72], a natural new direction was to explore psyche-delics in depression.”
Romeo, B., Kervadec, E., Fauvel, B., Strika-Bruneau, L., Mathieu, P., Amirouche, A., Bezo, A., Hacquet, R., Piolino, P., & Benyamina, A. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111621 · Cited by 2
Carlisle, N. A., Simonsson, O., MacCarthy, S., Elliott, M. N., Miller, G. H., Goldberg, S. B., Shallcross, R. A., & Hendricks, P. S. (2026) · Scientific Reports · doi:10.1038/s41598-026-37609-5 · Cited by 4
“…who endorsed lifetime psychedelic use in the dataset that was nationally representative of US adults in terms of age, race/ethnicity, and sex (Study 1), 18.4% ( n = 113) reported at least one major life change that they attributed to their experiences with psychedelics (95% CI [15.4, 21.7]).”
InfluentialCohen, R., Bastos, J., Cunha, C., Marguilho, M., Sancho, A. V., Silva, M. J. M., King, F., & Castro-Rodrigues, P. (2026) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2026.02.001 · Cited by 3
Rudin, D., Ren, X., Liechti, M. E., Huang, N., & Arias, H. R. (2026) · Neurochemical Research · doi:10.1007/s11064-026-04727-5 · Cited by 3
Kuypers, K. P. C., Mason, N. L., Carlier, A., Totomanova, I., & Haijen, E. C. H. M. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03801-2 · Cited by 2
On the Edges: The Ethics of Human Studies with Psychedelic Substances
da Costa, S. C., & Sofuoglu, M. (2023) · Springer eBooks · doi:10.1007/978-3-031-14339-7_9 · Cited by 2
Near-Death Experiences and Spirituality
Greyson, B. (2024) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780190905538.013.27 · Cited by 3
Psychotropic Drugs Reemerging as Headache Medicines
Schindler, E. A. D. (2024) · CNS Drugs · doi:10.1007/s40263-024-01107-x · Cited by 2
“Ketamine also found its way into recreational circles for its acute out-of-body effects and alterations in sensation and perception that overlap with those of classic psychedelics [38].”
Miller, C. W. T., & Kozak, Z. (2025) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000425 · Cited by 2
Intentional Choices of Metaphors for Psychedelic-Assisted Therapy
Earleywine, M., MacConnel, H. A., & Leo, J. A. D. (2025) · Cognitive and Behavioral Practice · doi:10.1016/j.cbpra.2025.04.002 · Cited by 2
Kroeze, Y., Oti, M., Cooijmans, R. H. M., van Beusekom, E., Kroeze, L. I., Middelman, A., van Bokhoven, H., Kolk, S. M., Homberg, J. R., & Zhou, H. (2025) · Developmental Neurobiology · doi:10.1002/dneu.22973 · Cited by 2
“5-HT 5-HT 2A , encoded by the Htr2a gene, is a Gq coupled 5-HT receptor present on glutamatergic pyramidal cells in deep cortical layers (V and VI) (Vollenweider and Kometer 2010).”
InfluentialQuirce, C. M., & Balma, Q. (2011) · Americanae (AECID Library) · doi:10.15517/rr.v90i1.1480 · Cited by 2
Neurobiological Augmentation of Psychotherapy in Treatment Resistant Depression
Li, S. (2014) · Journal of Depression & Anxiety · doi:10.4172/2167-1044.s2-002 · Cited by 2
“Ketamine showed beneficial effects in treatment resistant depression (TRD) patients [14], through enhancing AMPA receptor function, altering glutamatergic neurotransmission in prefrontal limbic circuitries and leads to neuroplastic adaptations [105].”
BackgroundKetamine Treatment for Major Depression
Anand, A., Mathew, S. J., & Janicak, P. G. (2011) · Psychopharm Review · doi:10.1097/01.psyphr.0000410133.47951.30 · Cited by 2
Pharmacological assistance for psychotherapy
Lochtenberg, J., Kirshenbaum, A. P., & Johnson, M. W. (2021) · Emerging Trends in Drugs Addictions and Health · doi:10.1016/j.etdah.2021.100017 · Cited by 3
Risca, H. I. (2021) · Cited by 2
da Silva, J. R. M. Q., & Mendonça, M. A. (2023) · Revista Ibero-Americana de Humanidades, Ciências e Educação · doi:10.51891/rease.v9i8.11098 · Cited by 2
Psilocybin based therapy for cancer related distress, a systematic review and meta analysis
Bahi, C. (2019) · arXiv (Cornell University) · doi:10.48550/arxiv.1910.05176 · Cited by 2
“…cancer related distress (Ostuzzi et al., 2015) A serotoninergic psychedelic substance, psilocybin (psilocyn) that is 5-HT2A receptors agonist (Vollenweider and Kometer, 2010) and induces various and importants modifications in perceptions, emotions and sensations (Halberstadt 2015) appear to…”
Backgroundde Moura, A. M., Aragão, M. B. D. M., Conceição, D. C. D. O., & Seixas, K. B. (2022) · Research Society and Development · doi:10.33448/rsd-v11i4.27182 · Cited by 5
Majić, T., Gouzoulis‐Mayfrank, E., & Schaub, M. (2018) · Elsevier eBooks · doi:10.1016/b978-3-437-23021-9.00012-6 · Cited by 2
Large language models auto-profile conscious awareness changes under psychedelic drug effectsPreprint
Bzdok, D., Carhart-Harris, R. L., Savignac, C., Bell, G., & Laureys, S. (2024) · Research Square · doi:10.21203/rs.3.rs-4670805/v1 · Cited by 3
Psilocin fosters neuroplasticity in iPSC-derived human cortical neuronsPreprint
Schmidt, M., Hoffrichter, A., Davoudi, M., Horschitz, S., Lau, T., Meinhardt, M. W., Spanagel, R., Ladewig, J., Köhr, G., & Koch, P. (2025) · eLife · doi:10.7554/elife.104006.1 · Cited by 4
What Conceptual Metaphors Appear in Texts on Psychedelics and Medicine? Corpus-Based Cognitive Study
Bryła, M. (2022) · Respectus Philologicus · doi:10.15388/respectus.2022.42.47.115 · Cited by 1
Psychedelics: Recent Philosophical Discussions
Letheby, C. (2024) · Springer eBooks · doi:10.1007/978-94-017-8706-2_101-1 · Cited by 2
The way of O: phenomenology of psychedelic use and the path to ultimate reality
Miller, C. W. T. (2024) · Psychodynamic Practice · doi:10.1080/14753634.2024.2371787 · Cited by 3
“These drugs have been shown, through their 5-HT2A agonistic action, to promote neuroplasticity via increased glutamatergic neurotransmission (Calder & Hasler, 2023; Vollenweider & Kometer, 2010).”
Esketamine-Induced Dissociation: A Case Report
Scarcella, J., MacDaniels, J. S., Coffin, L., & Schwartz, T. L. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2424283 · Cited by 1
“It has been described by researchers as a “pleasurable loss of ego boundaries” and “psychotic-like ego dissolution that involves fear and paranoid ideation” (Vollenweider and Kometer 2010).”
Afrooghe, A., Ahmadi, E., Lesani, A., Mehranjani, M. S., Elahi, M. M., Babaei, M., Shayan, M., Shafaroodi, H., Jafari, R. M., Foroumadi, A., et al. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04152-5 · Cited by 3
“…for the antidepressant outcomes of psilocybin-assisted therapy in patients facing life-threatening cancer or experiencing treatment-resistant depression, suggests the promise of psilocybin-assisted therapy as an innovative intervention for depression (Vollenweider and Kometer 2010; Nichols 2016).”
Exploring the importance of bodyset for the psychedelic experience and beyond
Uthaug, M. V., Allocca, G., Havenith, M. N., Szabó, A., Rosas, F. E., & Ramaekers, J. G. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2025.00418 · Cited by 2
Suay, D., Aicher, H., Singer, B., Mueller, M. J., Jelusic, A., Calzaferri, L., Springfeld, P., Dornbierer, D., & Scheidegger, M. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251353256 · Cited by 1
“This aligns with research suggesting that psychedelics may cause acute impairments but lead to post-acute cognitive enhancements, potentially through neuroplasticity-related mechanisms (Ly et al., 2018; Vollenweider and Kometer, 2010).”
Sleep Paralysis: Pathogenesis, Clinical Manifestations, and Treatment Strategies
Wang, Y., Li, Q., Zhong, Z., Ouyang, Q., Zou, X., Yue, K., & Yao, D. (2025) · Journal of Integrative Neuroscience · doi:10.31083/jin38979 · Cited by 2
“5-HT2A receptor activation in the visual cortex elicits visual hallucinations by increasing cortical excitability and altering visually evoked cortical responses, yet 5-HT2A receptors in the limbic system play a very important role in the regulation of fearful emotions [147,148].”
Lee, B., Kim, N. S., Bae, U., Choi, Y., Yang, C., & Lee, M. Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1565592 · Cited by 1
“…exhibits rapid and long-lasting antidepressant potential at a sub-anesthetic dose in both clinical and non-clinical studies, the NMDA receptor has been suggested as a novel pharmaceutical target for treating depression (Vollenweider and Kometer, 2010; Lindholm et al., 2012; Weston et al., 2021).”
Ricci, V., Chiappini, S., Martinotti, G., & Maina, G. (2025) · Healthcare · doi:10.3390/healthcare13243210 · Cited by 1
“…to be related to several patho-genetic mechanisms: higher levels of central dopamine for stimulants [16], cannabinoid CB1-receptor agonism for cannabis-related substances [17,18] 5HT2A-receptor agonism for hallucinogens [17], and NMDA receptor antagonism for dissociatives such as ketamine [18].”
Hooper, J., Williams, S. L., Mueller, R. L., & Hutchison, K. E. (2026) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2026.2727016 · Cited by 4
Tsang, V. W. L., Jones, T., Tsoi, S., Gorsuch, L., Dunn, R., & Schütz, C. G. (2026) · Psychedelics · doi:10.1016/j.psyche.2026.100009 · Cited by 1
Courtes, A. C., Myers, B., Daly, N., Jones, G., Soares, J. C., Zarate, C. A., & Machado‐Vieira, R. (2026) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2026.02.011 · Cited by 1
Sabé, M., Grof, P., Sackett, N. B., Tai, S., Kryskow, P., Bershad, A. K., Turkington, D., Buonarroti, M., Pieri, M. D., Baniotopoulos, P., et al. (2026) · Schizophrenia Research · doi:10.1016/j.schres.2026.03.003 · Cited by 1
Psychological support in psychedelic-assisted therapy clinical trials: A systematic review
Brusky, B., M’Baïlara, K., Alla, F., & Barrault, M. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261424204 · Cited by 2
“Subjective effects combined with a specific pharmacology that promotes neuroplasticity are thought to make psychedelics especially sensitive to context (Vollenweider and Kometer, 2010; Yaden and Griffiths, 2021).”
Egger, K., Bozsak, R., Aicher, H., Sari, H., Poetzsch, S. N., Rominger, A., Martin-Soelch, C., Smallridge, J. W., Dornbierer, D., Quednow, B. B., et al. (2026) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x261454172 · Cited by 2
Guidetti, C., Fava, M., & Papakostas, G. I. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03722-0 · Cited by 1
“Finally, 5-HT2A receptor activation has been shown to drive neuroplastic changes that may underlie the sustained effects observed after psychedelic sessions [23, 35, 36].”
(Es)ketamine in functional neurological disorder: a systematic review
Tamilson, B., Chitolie, M., Coebergh, J. A., Agrawal, N., Poole, N. A., Butler, M., Kanaan, R., & Nicholson, T. R. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1872389 · Cited by 2
Lysergic Acid Diethylamide and Mystical Experiences
Lyvers, M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800212-4.00078-9 · Cited by 1
Lazzaretti, M., Mandolini, G. M., Altamura, A. C., & Brambilla, P. (2018) · Springer eBooks · doi:10.1007/978-3-319-75124-5_2 · Cited by 1
The How and Why of Psychedelics
Jinks, T. (2019) · Springer eBooks · doi:10.1007/978-3-030-28902-7_18 · Cited by 1
How Much Crime Is Drug-Related?
R.Kleiman, M. A., Caulkins, J. P., & Hawken, A. (2011) · Oxford University Press eBooks · doi:10.1093/wentk/9780199764518.003.0007 · Cited by 1
Betzler, F., & Majić, T. (2017) · Springer eBooks · doi:10.1007/978-3-642-55125-3_48 · Cited by 1
Drogen- und Medikamentenabhängigkeit
Majić, T., Mick, I., Kienast, T., Heinz, A., & Soyka, M. (2016) · Springer Reference Medizin · doi:10.1007/978-3-642-45028-0_62-1 · Cited by 1
Neurobiologische Grundlagen der Wirkung von Psychedelika
Vollenweider, F. X., & Preller, K. H. (2016) · Springer eBooks · doi:10.1007/978-3-642-55214-4_70-1 · Cited by 1
Self-citationUso de psicodélicos para tratamento de transtornos psiquiátricos: uma revisão integrativa
de Souza, P. H. M., & Souza, G. P. (2023) · Bionorte · doi:10.47822/bn.v12isuppl.2.528 · Cited by 2
Psilocybin, Depression, and Synaptogenesis: Insights into the Field’s Past, Present, and Future
Douglas, A. C., Staas, D. J., Hampton, A., Burns, K., & Suter, F. (2023) · Georgetown Scientific Research Journal · doi:10.48091/gsr.v3i2.62 · Cited by 2
Evaluating the Therapeutic Utility of Hallucinogens for Substance Use Disorders
Dakwar, E. (2014) · Springer eBooks · doi:10.1007/978-88-470-5322-9_33 · Cited by 1
Arce, J. M. R. (2012) · Dialnet (Universidad de la Rioja) · Cited by 1
Psychedelics and the media in the Visegrad countries
Feher, O. (2018) · Journal of Psychedelic Studies · doi:10.1556/2054.2018.007 · Cited by 4
Novel harmala-ocudelic tuning (HOT) for ocular disorders
Lansky, E. S. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.109834 · Cited by 1
Psychedelics re-engineered for potential use in the clinic
Manzano-Nieves, G., & Liston, C. M. (2020) · Nature · doi:10.1038/d41586-020-03404-z · Cited by 2
Soyka, M. (2018) · Elsevier eBooks · doi:10.1016/b978-3-437-23021-9.00018-7 · Cited by 1
Psilocybin Therapy for Major Depressive Disorder: A Systematic Review
Venugopal, K. (2023) · Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal · doi:10.26685/urncst.489 · Cited by 3
“…psychedelic experiences (APE) that are characterized by visual and auditory hallucinations (synesthesia); alterations in perception, thought processes, and emotions; profound changes in mood, cognition, and behaviour; decreased rumination, and; increased introspection and ego-dissolution [9-10].”
BackgroundEl proceso evolutivo de la humanidad a través de Psilocybe
Serrano, L., Romero, O. S. G., & Romero-Bautista, L. (2023) · Ciencias Sociales y Religión · doi:10.20396/csr.v25i00.8672182 · Cited by 1
Ayahuasca: farmacología, efectos agudos, potencial terapéutico y rituales
Aliño, M., Gadea, M., Miguel, J. P. S., & Espert, R. (2015) · Repository of Digital Objects for Teaching Research and Culture (University of Valencia) · Cited by 3
Lim, C. H., Kangas, B. D., & Bergman, J. (2018) · doi:10.22186/jyi.35.2.45-49 · Cited by 1
Are Psychedelics Something New in Teaching Psychopharmacology?
Louie, A. K., Beresin, E. V., Coverdale, J., Balon, R., Guerrero, A. P. S., Morreale, M. K., Aggarwal, R., & Brenner, A. M. (2020) · Academic Psychiatry · doi:10.1007/s40596-020-01294-x · Cited by 2
Journey To The Centre Of The Mind: Psychedelic Treatment of Mental Health in Aotearoa
Lutyens, D. (2023) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.21904854 · Cited by 3
The Efficacy of PRISTINE: Revealing Concealed Opioid Crisis Trends via Reddit ExaminationPreprint
Alhamadani, A., Sarkar, S., Behal, S., Alkulaib, L., & Lu, C. (2023) · Research Square · doi:10.21203/rs.3.rs-2758553/v1 · Cited by 2
N, N-Dimethyltryptamine and harmine formulation shifts metastable topography sequences in the cortexPreprint
Niedernhuber, M., Suay, D., Mueller, M., Scheidegger, M., Dornbierer, D., & Aicher, H. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.04.692302 · Cited by 1
“Psychedelics are psychoactive drugs which produce temporary changes in emotion, perception and cognition not readily explained by altered sensory input or diminished wakefulness (Vollenweider & Kometer, 2010).”
Zamarrenho, L. G. (2014) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.59.2014.tde-17102014-103415
Zur Bedeutung der experimentellen Psychosenforschung in der Psychiatrie
Geppert, M., & Hermle, L. (2014) · Nervenheilkunde · doi:10.1055/s-0038-1627719
Ml, C., & Balma, Q. (2011) · Dialnet (Universidad de la Rioja)
Palhano-Fontes, F. (2012) · Americanae (AECID Library) · Cited by 5
West, H. C. (2010) · ThinkTech (Texas Tech University)
Specific modalities of treatment
McGrath, P. J., & Roose, S. P. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139175869.024
Ketamine Usage at Subanesthetic Doses and Psychoactive Effects
Flack, D., & Dakwar, E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800212-4.00063-7
Neurotransmitter and neuropeptide control of hypothalamic, pituitary and other hormones
Wilkinson, M., & Brown, R. E. (2015) · Cambridge University Press eBooks · doi:10.1017/cbo9781139045803.007
Arcadian Electrickery: Locating “Englishness” in England's Psytrance Culture and Sonic Aesthetic
Farrell, G. L. (2015) · IGI Global eBooks · doi:10.4018/978-1-4666-8665-6.ch012
Metadata
- Authors
- Vollenweider, F. X., & Kometer, M.
- Affiliations
- University of Zurich (CH)
- University Hospital Zurich (CH)
- Corresponding author
- Vollenweider, Franz X.
- Venue
- Nature Reviews Neuroscience
- Published
- 2010-08-18
- Volume
- 11
- Issue
- 9
- Pages
- 642-651
- ISSN
- 1471-003X (ISSN-L)
- 1471-0048
- OpenAlex
- W2068751924
- Semantic Scholar
- d95a57f4b1e3288f21a7dab08ebc2fd5ff10a762
- Cited by
- 723
- References
- 149
- Citations by year
- 2026: 55 · 2025: 75 · 2024: 55 · 2023: 64 · 2022: 53 · 2021: 63 · 2020: 50 · 2019: 35 · 2018: 56 · 2017: 37 · 2016: 48 · 2015: 29 · 2014: 24 · 2013: 18 · 2012: 25
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- psychedelics, mood disorders, serotonergic system, glutamatergic system, dissociative anesthetics, LSD, psilocybin, ketamine, neuroplasticity, neural circuits, psychiatric treatment
- MeSH terms
- Animals, Brain, Hallucinogens, Humans, Models, Neurological, Mood Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.